WeVote
Log In

Bill

Bill

HB 27

Maryland Technology Development Corporation - Long COVID Innovation Grant and Loan Program

2026 Regular Session Introduced by Greg Wims

Maryland establishes a Long COVID innovation grant and loan program through the Technology Development Corporation to fund treatment and diagnostic development, accelerating therapies for affected residents.

Hearing 2/10 at 2:00 p.m.
0
WeVote Research Nonpartisan
Bill Summary · HB 27

Legislative bill overview

HB 27 establishes a Long COVID Innovation Grant and Loan Program administered by the Maryland Technology Development Corporation to fund research, development, and commercialization of treatments and diagnostics for Long COVID. The bill provides financial support and incentives for businesses and researchers working on Long COVID-related innovations.

Why is this important

Long COVID affects hundreds of thousands of Marylanders with debilitating symptoms and limited treatment options, creating significant healthcare and economic burden. By directing funding toward innovation in this area, the bill could accelerate development of therapies while positioning Maryland as a leader in emerging biotech sectors, potentially creating jobs and attracting industry investment.

Potential points of contention

  • Funding source and fiscal impact: The bill's cost and whether dedicated funding is specified or if it competes with other state priorities remains unclear from available information
  • Program scope and oversight: Questions about which entities qualify, how success is measured, and whether grants/loans will be efficiently distributed given Long COVID's complex and variable presentation
  • Evidence of effectiveness: Long COVID research is still evolving; uncertainty about whether state-directed funding will produce commercially viable or clinically meaningful outcomes compared to federal research initiatives

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.